Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020089760 - FIXED DOSE PHARMACEUTICAL COMPOSITION COMPRISING COMBINATION OF REMOGLIFLOZIN OR SALT OR ESTER THEREOF AND VILDAGLIPTIN OR SALT THEREOF

Publication Number WO/2020/089760
Publication Date 07.05.2020
International Application No. PCT/IB2019/059196
International Filing Date 27.10.2019
IPC
A61K 9/20 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
A61K 9/24 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
22Sustained or differential release type
24Layered or laminated unitary dosage forms
A61K 31/7056 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
7056containing five-membered rings with nitrogen as a ring hetero atom
Applicants
  • GLENMARK PHARMACEUTICALS LIMITED [IN]/[IN]
Inventors
  • MAHAJAN, Narayan
  • DESHMUKH, Nitin
  • DHUPPAD, Ulhas
  • MANDADI, Sravan
  • MISRA, Chandrasekhar
  • KODGULE, Rahul
  • TANDON, Monika
Priority Data
20182104135001.11.2018IN
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) FIXED DOSE PHARMACEUTICAL COMPOSITION COMPRISING COMBINATION OF REMOGLIFLOZIN OR SALT OR ESTER THEREOF AND VILDAGLIPTIN OR SALT THEREOF
(FR) COMPOSITION PHARMACEUTIQUE À DOSE FIXE COMPRENANT UNE COMBINAISON DE REMOGLIFLOZINE OU D'UN SEL OU D'UN ESTER DE CELLE-CI ET DE VILDAGLIPTINE OU D'UN SEL DE CELLE-CI
Abstract
(EN)
The invention relates to a combination of remogliflozin or salt or ester thereof and DPP-IV inhibitor or salt thereof. In particular, the invention relates to a fixed dose pharmaceutical composition comprising a combination of remogliflozin or salt or ester thereof and DPP-IV inhibitor or salt thereof. Disclosed is the invention relates to a fixed dose pharmaceutical composition comprising a combination of remogliflozin or salt or ester thereof and vildagliptin or salt thereof; wherein the combination produces synergistic effect in reducing blood glucose levels in patients with diabetes. Also disclosed process of preparing pharmaceutical composition thereof.
(FR)
L'invention concerne une combinaison de remogliflozine ou d'un sel ou d'un ester pharmaceutiquement acceptable de celle-ci et d'un inhibiteur de DPP-IV ou d'un sel pharmaceutiquement acceptable de celui-ci. En particulier, l'invention concerne une composition pharmaceutique à dose fixe comprenant une combinaison de remogliflozine ou d'un sel ou d'un ester de celle-ci et d'un inhibiteur de DPP-IV ou d'un sel de celui-ci. L'invention concerne une composition pharmaceutique à dose fixe comprenant une combinaison de remogliflozine ou d'un sel ou d'un ester de celle-ci et de vildagliptine ou d'un sel de celle-ci ; la combinaison produisant un effet synergique réduisant les taux de glycémie chez des patients atteints de diabète. L'invention concerne également un procédé de préparation de la composition pharmaceutique.
Latest bibliographic data on file with the International Bureau